Metis Global Partners LLC Purchases 2,684 Shares of DexCom, Inc. (NASDAQ:DXCM)

Metis Global Partners LLC boosted its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 14.5% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 21,166 shares of the medical device company’s stock after buying an additional 2,684 shares during the period. Metis Global Partners LLC’s holdings in DexCom were worth $1,419,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in DXCM. Avantax Advisory Services Inc. grew its holdings in shares of DexCom by 35.4% during the first quarter. Avantax Advisory Services Inc. now owns 3,601 shares of the medical device company’s stock worth $499,000 after purchasing an additional 942 shares in the last quarter. Orion Portfolio Solutions LLC grew its stake in DexCom by 31.9% in the 1st quarter. Orion Portfolio Solutions LLC now owns 9,871 shares of the medical device company’s stock worth $1,369,000 after buying an additional 2,388 shares in the last quarter. M&G Plc bought a new position in shares of DexCom in the 1st quarter worth $8,129,000. Intech Investment Management LLC purchased a new stake in shares of DexCom during the 1st quarter valued at $2,575,000. Finally, Acadian Asset Management LLC lifted its holdings in shares of DexCom by 40.3% during the 1st quarter. Acadian Asset Management LLC now owns 8,008 shares of the medical device company’s stock worth $1,109,000 after acquiring an additional 2,299 shares during the last quarter. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

DexCom Stock Up 1.6 %

Shares of NASDAQ:DXCM opened at $75.88 on Friday. The stock’s 50-day moving average is $70.03 and its 200 day moving average is $91.67. The company has a market cap of $29.64 billion, a PE ratio of 45.44, a P/E/G ratio of 2.22 and a beta of 1.17. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12. DexCom, Inc. has a 1 year low of $62.34 and a 1 year high of $142.00.

Insider Transactions at DexCom

In related news, EVP Sadie Stern sold 426 shares of the firm’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $29,457.90. Following the completion of the sale, the executive vice president now owns 75,451 shares of the company’s stock, valued at $5,217,436.65. This trade represents a 0.56 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, COO Jacob Steven Leach sold 746 shares of the business’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $51,585.90. Following the transaction, the chief operating officer now directly owns 264,915 shares in the company, valued at approximately $18,318,872.25. The trade was a 0.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.30% of the company’s stock.

Analysts Set New Price Targets

DXCM has been the topic of a number of research analyst reports. Stifel Nicolaus increased their target price on DexCom from $90.00 to $100.00 and gave the company a “buy” rating in a research note on Friday, August 23rd. Leerink Partners reduced their price objective on DexCom from $90.00 to $87.00 and set an “outperform” rating on the stock in a research report on Friday, October 25th. Piper Sandler reaffirmed an “overweight” rating and issued a $90.00 target price on shares of DexCom in a research note on Monday, August 26th. Wells Fargo & Company lifted their price target on shares of DexCom from $80.00 to $90.00 and gave the stock an “overweight” rating in a research note on Friday, October 25th. Finally, Morgan Stanley cut their price objective on shares of DexCom from $120.00 to $75.00 and set an “equal weight” rating for the company in a research note on Friday, July 26th. Seven investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $104.59.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.